Phase I study of PM00104 (Zalypsis) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors Full Text
Investigational New Drugs, 06/21/2012
Clinical Article
Massard C et al. – PM00104 (Zalypsis) 2.0mg/m2 1–hour, infusion weekly for three consecutive weeks resting every fourth week (d1,8,15 q4wk) showed a positive risk–benefit ratio, which has supported its further evaluation in three ongoing phase II clinical trials.



